Literature DB >> 1816107

Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

I G Mitov1, D G Terziiski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1816107     DOI： 10.1007/BF01726444

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  77 in total

Review 1.  Monoclonal antibodies: technology and application to gram-negative infections.

Authors:  L S Young
Journal:  Infection       Date:  1984 Jul-Aug       Impact factor: 3.553

2.  Structure of the Core oligosaccharide from the lipopolysaccharide of Pseudomonas aeruginosa PAC1R and its defective mutants.

Authors:  P S Rowe; P M Meadow
Journal:  Eur J Biochem       Date:  1983-05-02

3.  Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects.

Authors:  A DeMaria; M A Johns; H Berberich; W R McCabe
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

4.  Binding activity of a murine anti-lipid A monoclonal antibody.

Authors:  K Elkins; E S Metcalf
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

5.  Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide.

Authors:  M I Marks; E J Ziegler; H Douglas; L B Corbeil; A I Braude
Journal:  J Clin Invest       Date:  1982-04       Impact factor: 14.808

6.  Lipid A antiserum-mediated protection against lipopolysaccharide- and lipid A-induced fever and skin necrosis.

Authors:  E T Rietschel; C Galanos
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

7.  Immunoprotective murine monoclonal antibodies specific for the outer-core polysaccharide and for the O-antigen of Escherichia coli 0111:B4 lipopolysaccharide (LPS).

Authors:  R T Coughlin; W C Bogard
Journal:  J Immunol       Date:  1987-07-15       Impact factor: 5.422

8.  Cross-reactive immunoprotective antibodies to Escherichia coli O111 rough mutant J5.

Authors:  R Sakulramrung; G J Domingue
Journal:  J Infect Dis       Date:  1985-06       Impact factor: 5.226

9.  Cross-reactivity of monoclonal antibodies to Escherichia coli J5 with heterologous gram-negative bacteria and extracted lipopolysaccharides.

Authors:  M K Aydintug; T J Inzana; T Letonja; W C Davis; L B Corbeil
Journal:  J Infect Dis       Date:  1989-11       Impact factor: 5.226

10.  Characterization of the susceptibility of Pseudomonas aeruginosa to complement-mediated killing: role of antibodies to the rough lipopolysaccharide on serum-sensitive strains.

Authors:  N L Schiller
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441
View more
  4 in total

1.  Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp.

Authors:  Raina T Gergova; Ianko D Iankov; Iana H Haralambieva; Ivan G Mitov
Journal:  Curr Microbiol       Date:  2007-01-05       Impact factor: 2.188

2.  Enhanced protection by use of a combination of anticapsule and antilipopolysaccharide monoclonal antibodies against lethal Escherichia coli O18K5 infection of mice.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; M Poppelier; K Kraaijeveld; J Verhoef
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

3.  Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides.

Authors:  H M Kuhn
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

Review 4.  Improving Immunotherapy Through Glycodesign.

Authors:  Matthew J Buettner; Sagar R Shah; Christopher T Saeui; Ryan Ariss; Kevin J Yarema
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.